“Partnering with global pharmaceutical and biotech companies offers an opportunity to build new networks”
Abion, an innovative pharmaceutical development company, announced on December 18 that it will participate in the ‘Biotech Showcase 2025’ in San Francisco, USA, from January 13 to 15 (local time) and the ‘Bio Partnering JPM Week’, which runs through January 16.
The Biotech Showcase 2025 and Bio Partnering events are held in conjunction with the ‘JP Morgan Healthcare Conference (JPM Week)’. These events will offer support to participants, including biotechnology companies and investors, to facilitate both virtual or in-person meetings.
The JP Morgan Healthcare Conference is the world’s largest pharmaceutical, biotechnology, and healthcare event, held annually in January. It serves as an international networking platform, bringing together over 9,000 attendees and more than 1,200 investors from around the world to share research findings, technologies and explore opportunities for business cooperation.
At the event, Abion plans to showcase its new pipelines, including ABN202 (antibody-cytokine fusion protein platform technology) and ABN501 (claudin-3 targeting antibody treatment), along with its key R&D advancements. The company recently revealed that it has accelerated the development of its innovative novel drug (First-In-Class), Vabametkib (ABN401), by filling for a change in its Phase 2 clinical trial plan (IND) to evaluate the safety and efficacy of the drug in combination with Lazertinib.
“This event will provide an opportunity to present our company’s innovative technology to investors and key executives in the biopharmaceutical industry, as well as establish new networks,” an Abion official said. “We have planned meetings with many new partners and investors. We will continue to engage with existing partners and focus on long-term development.”
Published by: https://www.thebionews.net/news/articleView.html?idxno=11543
